Quick Answer
ADC Therapeutics SA reported R&D Expense of $104.00 million for fiscal year 2025.
ADC Therapeutics SA R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $104.00M | -5.1% |
| 2024 | $109.63M | -13.8% |
| 2023 | $127.13M | -31.8% |
| 2022 | $186.46M | +18.0% |
| 2021 | $158.00M | +11.2% |
| 2020 | $142.03M | +32.1% |
| 2019 | $107.54M | -9.1% |
| 2018 | $118.31M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.80M | -17.5% | -10.9% |
| June 30, 2025 | $30.09M | +23.9% | +4.0% |
| March 31, 2025 | $28.93M | +12.4% | -11.0% |
| September 30, 2024 | $32.50M | +20.0% | +33.8% |
| June 30, 2024 | $24.30M | -22.5% | -5.6% |
| March 31, 2024 | $25.73M | -32.9% | -5.0% |
| September 30, 2023 | $27.08M | — | -13.6% |
| June 30, 2023 | $31.34M | — | -18.3% |
- ADC Therapeutics SA showed a decrease of -5.1% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, ADC Therapeutics SA’s r&d expense has declined by 12.1% (from $118.31 million to $104.00 million).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: